Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06504394 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
A Phase 2 study of Primary Mediastinal Large B-Cell Lymphoma Recurrent and Primary Mediastinal Large B-Cell Lymphoma Refractory, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 20
- Study locations
NCT06504394 is a Phase 2 study of Primary Mediastinal Large B-Cell Lymphoma Recurrent and Primary Mediastinal Large B-Cell Lymphoma Refractory that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 66 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT06504394, a Phase 2 study of Primary Mediastinal Large B-Cell Lymphoma Recurrent and Primary Mediastinal Large B-Cell Lymphoma Refractory, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of the study is to assess the pharmacokinetics (PK) profile of pembrolizumab following subcutaneous (SC) injection of pembrolizumab coformulated with hyaluronidase, and to evaluate the objective response rate (ORR) of pembrolizumab (+) berahyaluronidase alfa SC in adult participants with Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL). There is no formal hypothesis to be tested for this study.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab (+) Berahyaluronidase alfa
Study Locations (20)
Region M. de Santiago
- FALP ( Site 0207) - Santiago
- Clínica Inmunocel ( Site 0201) - Santiago
- Bradfordhill-Clinical Area ( Site 0202) - Santiago
Other
- Centro de Investigacion Clinica de Oaxaca ( Site 0405) - Oaxaca City
- Auckland City Hospital ( Site 1001) - Auckland
- Seoul National University Hospital-Oncology ( Site 1101) - Seoul
Iowa
- University of Iowa-Holden Comprehensive Cancer Center ( Site 0115) - Iowa City
- University of Iowa - Waukee ( Site 0111) - Waukee
Nevada
- Comprehensive Cancer Centers of Nevada ( Site 0114) - Las Vegas
New York
- Clinical Research Alliance ( Site 0101) - Westbury
New South Wales
- Westmead Hospital ( Site 0901) - Westmead
Coquimbo Region
- IC La Serena Research ( Site 0204) - La Serena
Región del Biobío
- Biocenter ( Site 0203) - Concepción
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2028-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06504394
The ClinicalTrials.gov registry entry for NCT06504394 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Primary Mediastinal Large B-Cell Lymphoma Recurrent appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab (+) Berahyaluronidase alfa is the first listed.
NCT06504394 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Region M. de Santiago, Other, Iowa.
Frequently Asked Questions
What is clinical trial NCT06504394 about?
NCT06504394 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)". The primary purpose of the study is to assess the pharmacokinetics (PK) profile of pembrolizumab following subcutaneous (SC) injection of pembrolizumab coformulated with hyaluronidase, and to evaluate the objective response rate (ORR) of pembrolizumab (+) berahyaluronidase alfa SC in adult participa...
What is the current status of trial NCT06504394?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2024-10-14. Estimated completion is 2028-11-08.
What conditions does trial NCT06504394 study?
This clinical trial studies the following conditions: Primary Mediastinal Large B-Cell Lymphoma Recurrent, Primary Mediastinal Large B-Cell Lymphoma Refractory, Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory.
What interventions are being tested in trial NCT06504394?
The interventions under investigation include: Pembrolizumab (+) Berahyaluronidase alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT06504394?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06504394 being conducted?
This trial has 20 study locations across Iowa, Nevada, New York, New South Wales, Coquimbo Region. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Mediastinal Large B-Cell Lymphoma Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Primary Mediastinal Large B-Cell Lymphoma Recurrent
All registered trials for this condition
Primary Mediastinal Large B-Cell Lymphoma Refractory
All registered trials for this condition
Iowa
All trials with a study site in Iowa
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.